JSPR250117P25000
- 6.58
- -0.97-12.85%
Jasper Therapeutics Newsroom
Jasper Launches AI Studio, Empowering Enterprise Marketing Teams to Build & Scale Generative AI Solutions
Insider Sale: Chief Operating Officer of $JSPR (JSPR) Sells 900 Shares
BMO Capital Initiates Coverage On Jasper Therapeutics With Outperform Rating, Announces Price Target of $63
Jasper Therapeutics Analyst Ratings
BMO Capital Initiates Jasper Therapeutics(JSPR.US) With Buy Rating, Announces Target Price $63
Express News | Jasper Therapeutics Inc - Initial Data Expected in Second Half of 2025
Express News | Jasper Therapeutics Announces First Patient Dosed in Phase 1B/2a Etesian Clinical Study of Briquilimab in Asthma
Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a ETESIAN Clinical Study of Briquilimab in Asthma
We're Keeping An Eye On Jasper Therapeutics' (NASDAQ:JSPR) Cash Burn Rate
Is Jasper Therapeutics (NASDAQ:JSPR) In A Good Position To Deliver On Growth Plans?
Is Jasper Therapeutics (JSPR) the Best Multibagger Stock to Buy Heading Into 2025?
Jasper Therapeutics to Participate at Upcoming Investor Conferences
Jasper Launches the Industry's First AI Knowledge Layer Built Specifically for Marketing
Stifel Maintains Jasper Therapeutics(JSPR.US) With Buy Rating, Maintains Target Price $80
RBC Capital Maintains Jasper Therapeutics(JSPR.US) With Buy Rating, Maintains Target Price $68
A Quick Look at Today's Ratings for Jasper Therapeutics(JSPR.US), With a Forecast Between $60 to $70
Jasper Therapeutics Advances in Antibody Therapy Development
Promising Outlook for Jasper Therapeutics: Buy Rating Reinforced by Advancements in Briquilimab
8-K: Jasper Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Jasper Therapeutics 3Q Loss/Shr $1.24 >JSPR